Saltar al contenido
Merck

A5922

Sigma-Aldrich

Amifostine trihydrate

≥97% (TLC), powder

Sinónimos:

2-(3-Aminopropyl)aminoethyl phosphorothioate, WR2721

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C5H15N2O3PS · 3 H2O
Número de CAS:
Peso molecular:
268.27
Número MDL:
Código UNSPSC:
12352200
ID de la sustancia en PubChem:
NACRES:
NA.77

Nivel de calidad

Ensayo

≥97% (TLC)

Formulario

powder

temp. de almacenamiento

2-8°C

cadena SMILES

OP(SCCNCCCN)(O)=O.O.O.O

InChI

1S/C5H15N2O3PS.3H2O/c6-2-1-3-7-4-5-12-11(8,9)10;;;/h7H,1-6H2,(H2,8,9,10);3*1H2

Clave InChI

TXQPXJKRNHJWAX-UHFFFAOYSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Aplicación

Amifostine may provide renal protection during PRRT using somatostatin analogs by mitigating radiation damage and reducing the absorbed kidney radiation dose. Amifostine remediates the degenerative effects of radiation on the mineralization capacity of the murine mandible.

Acciones bioquímicas o fisiológicas

Radioprotective agent. Selectively protects normal tissues from the damaging effects of anti-neoplastic radiation therapy. Selectivity is due to preferential uptake by normal tissues and subsequent metabolic activation to 2-(3-aminopropyl)aminoethanethiol.

Pictogramas

Exclamation mark

Palabra de señalización

Warning

Frases de peligro

Clasificaciones de peligro

Acute Tox. 4 Oral

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Punto de inflamabilidad (°F)

Not applicable

Punto de inflamabilidad (°C)

Not applicable

Equipo de protección personal

dust mask type N95 (US), Eyeshields, Gloves


Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Ourania Nicolatou-Galitis et al.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 21(1), 357-364 (2012-10-12)
The aim of this study was to review the available literature from 1966 until December 31, 2010 and define clinical practice guidelines for the use of amifostine for the prevention and treatment of oral mucositis in cancer patients. A systematic
Melanie Duval et al.
Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale, 41(5), 309-315 (2012-10-25)
The effectiveness of amifostine in the prevention of cisplatin ototoxicity remains controversial. The objective of this meta-analysis was to determine whether amifostine is successful in preventing ototoxicity secondary to cisplatin chemotherapy. Meta-analysis. We conducted a systematic review of all randomized
Henry L Gómez et al.
Hematology/oncology and stem cell therapy, 5(3), 152-157 (2012-10-26)
We report the 8-year follow-up of 34 patients aged ≥69 years old with NHL included in a phase IIb open-label randomized parallel groups study to evaluate the effectiveness of amifostine in preventing the toxicity of cyclophosphamide, doxorubicin, vincristine and prednisone
Murat Caloglu et al.
Journal of cancer research and therapeutics, 8(2), 260-265 (2012-07-31)
The aim of the study was to compare the protective efficacy of l-carnitine (LC) to amifostine on radiation-induced acute small intestine damage. Thirty, 4-week-old Wistar albino rats were randomly assigned to four groups - Group 1: control (CONT, n =
Michael I Koukourakis et al.
International journal of radiation oncology, biology, physics, 85(1), e7-13 (2012-10-09)
Postmastectomy radiation therapy (PMRT) provides major local control and survival benefits. More aggressive radiation therapy schemes may, however, be necessary in specific subgroups, provided they are safely administered. We report the tolerance and efficacy of a highly accelerated and hypofractionated

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico